Skip to Content

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

A new study “SunRISe-1” investigates the rate of complete response in patients with high-risk non-muscle-invasive bladder cancer treated with TAR-200 and/or systemic cetrelimab.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top